We are live on ! Find out more
HRTX icon

Heron Therapeutics

100 hedge funds and large institutions have $1.07B invested in Heron Therapeutics in 2017 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 49 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

227% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 15

56% more capital invested

Capital invested by funds: $690M → $1.07B (+$385M)

50% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 16

1% more funds holding

Funds holding: 99100 (+1)

0.64% less ownership

Funds ownership: 134.39%133.75% (-0.64%)

19% less call options, than puts

Call options by funds: $1.36M | Put options by funds: $1.68M

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

Holders
100
Holders Change
+1
Holders Change %
+1.01%
% of All Funds
2.49%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.1%
New
24
Increased
49
Reduced
15
Closed
16
Calls
$1.36M
Puts
$1.68M
Net Calls
-$323K
Net Calls Change
-$13M
Name Holding Trade Value Shares
Change
Change in
Stake
TCM
1
Tang Capital Management
California
$130M +$34M +2,457,716 +40%
Franklin Resources
2
Franklin Resources
California
$127M +$10.6M +767,527 +10%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$120M +$29.9M +2,158,041 +37%
JHIU
4
Janus Henderson Investors US
Colorado
$82.5M +$12.8M +925,948 +20%
BC
5
Broadfin Capital
New York
$74.2M +$14.5M +1,047,816 +27%
PHS
6
PFM Health Sciences
California
$59M +$16.6M +1,199,453 +44%
Invesco
7
Invesco
Georgia
$43.4M +$31.9M +2,306,098 +394%
BBA
8
Baker Bros. Advisors
New York
$41.8M +$5.54M +400,000 +17%
BlackRock
9
BlackRock
New York
$39.8M +$36.7M +2,652,008 +93,479%
KCM
10
Kingdon Capital Management
New York
$39.3M -$2.64M -190,443 -7%
CC
11
Carlson Capital
Texas
$33M +$30.5M +2,201,160 New
Vanguard Group
12
Vanguard Group
Pennsylvania
$28.1M +$7.44M +537,563 +40%
State Street
13
State Street
Massachusetts
$26.8M +$5.81M +420,113 +31%
HCMT
14
Highland Capital Management (Texas)
Texas
$24.7M +$1.13M +81,335 +5%
RCMNY
15
Rubric Capital Management (New York)
New York
$24M +$14.5M +1,050,000 +191%
Citadel Advisors
16
Citadel Advisors
Florida
$19.3M +$15.3M +1,106,946 +626%
CAM
17
Cormorant Asset Management
Massachusetts
$18M -$10.4M -751,263 -39%
Balyasny Asset Management
18
Balyasny Asset Management
Illinois
$18M +$16.6M +1,196,715 New
Alyeska Investment Group
19
Alyeska Investment Group
Illinois
$11.9M +$3.77M +272,734 +52%
Deutsche Bank
20
Deutsche Bank
Germany
$10.5M +$6.12M +441,883 +173%
O
21
OrbiMed
New York
$9.75M +$9M +650,000 New
ACH
22
ArrowMark Colorado Holdings
Colorado
$7.8M +$7.2M +520,169 New
Northern Trust
23
Northern Trust
Illinois
$7.59M +$1.93M +139,368 +38%
PAM
24
Panagora Asset Management
Massachusetts
$6.63M +$2.33M +168,202 +61%
TCP
25
Tourbillon Capital Partners
New York
$6.15M +$5.67M +410,000 New

HRTX Hedge Fund Activity: Q1 2017 in Review

100 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2017, worth a combined $1.07B — up 56% from $690M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new HRTX positions and 16 closed out — a net gain of 8 holders — while 49 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $36.7M. The largest seller was Cormorant Asset Management, cutting an estimated $10.4M.

  • 100 institutional investors held Heron Therapeutics (HRTX) as of Q1 2017, up from 99 in Q4 2016.
  • Funds reported $1.07B of Heron Therapeutics stock for Q1 2017, up 56% quarter-over-quarter.
  • 24 funds opened new Heron Therapeutics positions in Q1 2017 and 16 closed out, a net change of +8 holders.
  • The largest Heron Therapeutics buyer in Q1 2017 was BlackRock, an estimated $36.7M added.
  • The largest Heron Therapeutics seller in Q1 2017 was Cormorant Asset Management, an estimated $10.4M sold.

Based on aggregated 13F filings for Q1 2017.